Status:

RECRUITING

MRE Predictors of Disease Relapse After Stopping Biologics

Lead Sponsor:

University College, London

Collaborating Sponsors:

British Society of Gastrointestinal and Abdominal Radiology (BSGAR)

Conditions:

Crohn's Disease

Eligibility:

All Genders

16+ years

Brief Summary

This study aims to investigate if MR Enterography (MRE) improves the ability to predict which Crohn's disease patients will relapse quickly (disease comes back) after stopping biologic medication. MRE...

Detailed Description

This study aims to investigate if MR Enterography (MRE) improves the ability to predict which Crohn's disease patients will relapse (disease comes back) after stopping biologic medication when clinica...

Eligibility Criteria

Inclusion

  • Luminal small bowel or colonic Crohn's disease in clinical remission
  • 16 years or older
  • MRE as part of routine care performed within three months prior, or one month after the decision to stop biologic therapy Anti-TNF (Adalimumab, infliximab, Certolizumab) IL-23 or IL-12 antagonists (Ustekinumab) Anti-integrin biologics (Natalizumab, Vedolizumab)
  • Biologic therapy stopped due to clinical remission only
  • Definition of clinical remission: There is no agreed consensus on how clinical remission is defined and practice differs between hospitals and patients. To mirror current clinical practice, no strict definition of clinical remission will therefore be used. Detailed clinical parameters the time of stopping biologic agents will be collected.

Exclusion

  • \<16 years of age
  • Non-biological therapy, unless part of combination therapy with biologic agents
  • Biological therapy stopped for other reasons e.g. loss of effect, side effects
  • Resection of diseased segment(s) after MRE but before stopping biologic agent.
  • No MRE with the time window defined by eligibility criteria

Key Trial Info

Start Date :

February 27 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2027

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT06124287

Start Date

February 27 2024

End Date

February 1 2027

Last Update

May 13 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University College London Hospital

London, United Kingdom, NW1 2PG